
Bruck Kifle
Examiner (ID: 6836, Phone: (571)272-0668 , Office: P/1624 )
| Most Active Art Unit | 1624 |
| Art Unit(s) | 1624, 1611, 1622, 1202 |
| Total Applications | 3432 |
| Issued Applications | 2601 |
| Pending Applications | 218 |
| Abandoned Applications | 651 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17385557
[patent_doc_number] => 20220033409
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-03
[patent_title] => BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/343341
[patent_app_country] => US
[patent_app_date] => 2021-06-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 52496
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17343341
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/343341 | BRM targeting compounds and associated methods of use | Jun 8, 2021 | Issued |
Array
(
[id] => 18666220
[patent_doc_number] => 11773097
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-03
[patent_title] => Polymorphs of sepiapterin and salts thereof
[patent_app_type] => utility
[patent_app_number] => 17/342910
[patent_app_country] => US
[patent_app_date] => 2021-06-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 22
[patent_no_of_words] => 17857
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17342910
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/342910 | Polymorphs of sepiapterin and salts thereof | Jun 8, 2021 | Issued |
Array
(
[id] => 18145997
[patent_doc_number] => 20230019853
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-19
[patent_title] => MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/341877
[patent_app_country] => US
[patent_app_date] => 2021-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 84226
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 6
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17341877
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/341877 | Melanocortin 4 receptor antagonists and uses thereof | Jun 7, 2021 | Issued |
Array
(
[id] => 18628109
[patent_doc_number] => 20230286934
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-14
[patent_title] => Use of Multi-Kinase Inhibitors to Treat RNA Virus Infections
[patent_app_type] => utility
[patent_app_number] => 18/008282
[patent_app_country] => US
[patent_app_date] => 2021-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11774
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18008282
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/008282 | Use of Multi-Kinase Inhibitors to Treat RNA Virus Infections | Jun 7, 2021 | Pending |
Array
(
[id] => 18524263
[patent_doc_number] => 20230234920
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => Azirine Containing Compounds as Anti-Angiogenesis Agents and a Process for the Preparation Thereof
[patent_app_type] => utility
[patent_app_number] => 18/007960
[patent_app_country] => US
[patent_app_date] => 2021-06-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15967
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18007960
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/007960 | Azirine Containing Compounds as Anti-Angiogenesis Agents and a Process for the Preparation Thereof | Jun 3, 2021 | Pending |
Array
(
[id] => 17274376
[patent_doc_number] => 20210380574
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-09
[patent_title] => ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 17/335620
[patent_app_country] => US
[patent_app_date] => 2021-06-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38490
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -42
[patent_words_short_claim] => 1530
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17335620
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/335620 | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer | May 31, 2021 | Issued |
Array
(
[id] => 17214436
[patent_doc_number] => 20210347773
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-11
[patent_title] => ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS
[patent_app_type] => utility
[patent_app_number] => 17/328814
[patent_app_country] => US
[patent_app_date] => 2021-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23916
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17328814
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/328814 | Activator of TREK (TWIK RElated K | May 23, 2021 | Issued |
Array
(
[id] => 18620366
[patent_doc_number] => 11753394
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-09-12
[patent_title] => Synthesis of omecamtiv mecarbil
[patent_app_type] => utility
[patent_app_number] => 17/324867
[patent_app_country] => US
[patent_app_date] => 2021-05-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 8349
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17324867
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/324867 | Synthesis of omecamtiv mecarbil | May 18, 2021 | Issued |
Array
(
[id] => 18964147
[patent_doc_number] => 11897897
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-13
[patent_title] => Crystalline forms of cabotegravir sodium
[patent_app_type] => utility
[patent_app_number] => 17/324661
[patent_app_country] => US
[patent_app_date] => 2021-05-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 13990
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 101
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17324661
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/324661 | Crystalline forms of cabotegravir sodium | May 18, 2021 | Abandoned |
Array
(
[id] => 18451345
[patent_doc_number] => 20230192622
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => ANTI-SARS-COV-2 DRUG
[patent_app_type] => utility
[patent_app_number] => 17/926101
[patent_app_country] => US
[patent_app_date] => 2021-05-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9232
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17926101
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/926101 | ANTI-SARS-COV-2 DRUG | May 16, 2021 | Pending |
Array
(
[id] => 18435893
[patent_doc_number] => 20230183187
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => QUINAZOLINE COMPOUNDS AS INHIBITORS OF PREMATURE TERMINATION CODONS
[patent_app_type] => utility
[patent_app_number] => 17/998436
[patent_app_country] => US
[patent_app_date] => 2021-05-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10773
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 93
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17998436
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/998436 | QUINAZOLINE COMPOUNDS AS INHIBITORS OF PREMATURE TERMINATION CODONS | May 11, 2021 | Pending |
Array
(
[id] => 19011661
[patent_doc_number] => 11918561
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-03-05
[patent_title] => Treatment of breast cancer using combination therapies comprising GDC-9545 and a CDK4/6 inhibitor
[patent_app_type] => utility
[patent_app_number] => 17/316455
[patent_app_country] => US
[patent_app_date] => 2021-05-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 8519
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17316455
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/316455 | Treatment of breast cancer using combination therapies comprising GDC-9545 and a CDK4/6 inhibitor | May 9, 2021 | Issued |
Array
(
[id] => 19226690
[patent_doc_number] => 12006323
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-06-11
[patent_title] => Ethynyl derivatives
[patent_app_type] => utility
[patent_app_number] => 17/315349
[patent_app_country] => US
[patent_app_date] => 2021-05-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 5851
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17315349
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/315349 | Ethynyl derivatives | May 8, 2021 | Issued |
Array
(
[id] => 18420075
[patent_doc_number] => 20230174536
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => NOVEL COMPOUNDS FOR DIAGNOSIS
[patent_app_type] => utility
[patent_app_number] => 17/923771
[patent_app_country] => US
[patent_app_date] => 2021-05-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49971
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17923771
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/923771 | NOVEL COMPOUNDS FOR DIAGNOSIS | May 6, 2021 | Pending |
Array
(
[id] => 18739464
[patent_doc_number] => 20230348387
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-02
[patent_title] => NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/923878
[patent_app_country] => US
[patent_app_date] => 2021-05-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43407
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17923878
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/923878 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | May 5, 2021 | Pending |
Array
(
[id] => 17052082
[patent_doc_number] => 20210261516
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-26
[patent_title] => MYC G-QUADRUPLEX STABILIZING SMALL MOLECULES AND THEIR USE
[patent_app_type] => utility
[patent_app_number] => 17/306756
[patent_app_country] => US
[patent_app_date] => 2021-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26447
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17306756
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/306756 | MYC G-QUADRUPLEX STABILIZING SMALL MOLECULES AND THEIR USE | May 2, 2021 | Abandoned |
Array
(
[id] => 19151187
[patent_doc_number] => 11976083
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-05-07
[patent_title] => Inhibitors of peptidylarginine deiminases
[patent_app_type] => utility
[patent_app_number] => 17/242617
[patent_app_country] => US
[patent_app_date] => 2021-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 232504
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 530
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17242617
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/242617 | Inhibitors of peptidylarginine deiminases | Apr 27, 2021 | Issued |
Array
(
[id] => 18389832
[patent_doc_number] => 20230158050
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-25
[patent_title] => COMPOSITION FOR ENHANCING IMMUNE FUNCTION
[patent_app_type] => utility
[patent_app_number] => 17/921501
[patent_app_country] => US
[patent_app_date] => 2021-04-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4185
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17921501
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/921501 | COMPOSITION FOR ENHANCING IMMUNE FUNCTION | Apr 26, 2021 | Pending |
Array
(
[id] => 18434298
[patent_doc_number] => 20230181592
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES
[patent_app_type] => utility
[patent_app_number] => 17/920969
[patent_app_country] => US
[patent_app_date] => 2021-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11123
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 459
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17920969
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/920969 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | Apr 22, 2021 | Pending |
Array
(
[id] => 17035205
[patent_doc_number] => 20210252163
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-19
[patent_title] => IONIZABLE CATIONIC LIPID FOR RNA DELIVERY
[patent_app_type] => utility
[patent_app_number] => 17/234571
[patent_app_country] => US
[patent_app_date] => 2021-04-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29361
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 101
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17234571
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/234571 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | Apr 18, 2021 | Pending |